keyword
MENU ▼
Read by QxMD icon Read
search

Chemoradiation head and neck cancer

keyword
https://www.readbyqxmd.com/read/28790110/replication-stress-leading-to-apoptosis-within-the-s-phase-contributes-to-synergism-between-vorinostat-and-azd1775-in-hnscc-harboring-high-risk-tp53-mutation
#1
Noriaki Tanaka, Ameeta A Patel, Lin Tang, Natalie L Silver, Antje Lindemann, Hideaki Takahashi, Roman Jaksik, Xiayu Rao, Nene N Kalu, Tseng-Cheng Chen, Jiping Wang, Mitchell J Frederick, Faye M Johnson, Frederico Gleber-Netto, Siqing Fu, Marek Kimmel, Jing Wang, Walter N Hittelman, Curtis R Pickering, Jeffrey N Myers, Abdullah A Osman
Purpose: The cure rate for patients with advanced head and neck squamous cell carcinoma (HNSCC) remains poor due to resistance to standard therapy primarily consisting of chemoradiation. Since mutation of TP53 in HNSCC occurs in 60-80% of non-HPV associated cases and is in turn associated with resistance to these treatments, more effective therapies are needed. In this study, we evaluated the efficacy of a regimen combining vorinostat and AZD1775 in HNSCC cells with a variety of p53 mutations. <p>Experimental Design: Clonogenic survival assays and an orthotopic mouse model of oral cancer were used to examine the in vitro and in vivo sensitivity of high-risk mutant p53 HNSCC cell lines to vorinostat in combination with AZD1775...
August 8, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28780008/the-role-of-positron-emission-tomography-computed-tomography-imaging-in-head-and-neck-cancer-after-radical-chemoradiotherapy-a-single-institution-experience
#2
C Nelissen, J Sherriff, T Jones, P Guest, S Colley, P Sanghera, A Hartley
AIMS: Positron emission tomography/computed tomography (PET/CT) is used to restage head and neck cancer 3 months after chemoradiotherapy. The purpose of this study was to determine the negative predictive value (NPV) of a scan reported as having no abnormal uptake and the positive predictive values (PPV) for different maximum standardised uptake value (SUVmax) thresholds. MATERIALS AND METHODS: Patients with squamous cell carcinoma of the oro-/hypopharynx/larynx (n = 206) were included...
August 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28771728/quality-of-life-outcomes-of-transoral-robotic-surgery-with-or-without-adjuvant-therapy-for-oropharyngeal-cancer
#3
Rishabh Sethia, Ali C Yumusakhuylu, Isa Ozbay, Virginia Diavolitsis, Nicole V Brown, Songzhu Zhao, Lai Wei, Matthew Old, Amit Agrawal, Theodoros N Teknos, Enver Ozer
OBJECTIVES/HYPOTHESIS: To compare quality of life (QOL) of patients who underwent transoral robotic surgery (TORS) alone, with adjuvant radiation therapy (RT), or adjuvant chemoradiation therapy (CRT) in the treatment of oropharyngeal squamous cell cancer (OPSCCA). STUDY DESIGN: Prospective cohort study. METHODS: Medical records were reviewed for 111 patients treated for OPSCCA from 2008 to 2015. Patients were administered the Head and Neck Cancer Inventory (HNCI) to evaluate QOL preoperatively, and at 3 weeks, 3 months, 6 months, and 1 year postsurgery...
August 3, 2017: Laryngoscope
https://www.readbyqxmd.com/read/28764598/two-cases-of-combination-therapy-with-cetuximab-paclitaxel-and-cisplatin-for-advanced-head-and-neck-cancer
#4
Matthew A Hoch, Kati Cousins, Ruth Nartey, Keith Riley, Megan Hartranft
Two patients diagnosed with advanced head and neck cancer were treated with cetuximab 400 mg/m(2) intravenously for one loading dose followed by 250 mg/m(2) IV on days 1, 8, and 15 along with paclitaxel 80 mg/m(2) and cisplatin 30 mg/m(2) intravenously on days 1 and 8 repeated every 21 days for three cycles (CPP). Maintenance cetuximab 250 mg/m(2) intravenously weekly was continued following the aforementioned regimen for one year or until disease progression. Patient A was diagnosed with squamous cell carcinoma of the parotid gland treated initially with parotidectomy and radiation therapy...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/28751507/commentary-on-weekly-low-dose-versus-three-weekly-high-dose-cisplatin-for-concurrent-chemoradiation-in-locoregionally-advanced-non-nasopharyngeal-head-and-neck-cancer-a-systematic-review-and-meta-analysis-of-aggregate-data
#5
https://www.readbyqxmd.com/read/28731808/clinical-practice-in-pet-ct-for-the-management-of-head-and-neck-squamous-cell-cancer
#6
REVIEW
Reema Goel, William Moore, Baran Sumer, Saad Khan, David Sher, Rathan M Subramaniam
OBJECTIVE: The purpose of this article is to summarize the evidence for the value of PET/CT for the management of patients with head and neck squamous cell cancer and suggest best clinical practices. CONCLUSION: FDG PET/CT is a valuable imaging tool for identifying unknown primary tumors in patients with known cervical node metastases leading to management change and is the standard of care for the initial staging of stage III and IV head and neck squamous cell carcinomas (HNSCCs), for assessing therapy response when performed at least 12 weeks after chemoradiation therapy, and for avoiding unnecessary planned neck dissection...
August 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28728452/chemoradiation-induced-hearing-loss-remains-a-major-concern-for-head-and-neck-cancer-patients
#7
Nicole C Schmitt, Brandi R Page
OBJECTIVE: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. DESIGN: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. STUDY SAMPLE: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation...
July 20, 2017: International Journal of Audiology
https://www.readbyqxmd.com/read/28727137/national-evaluation-of-multidisciplinary-quality-metrics-for-head-and-neck-cancer
#8
John D Cramer, Sedona E Speedy, Robert L Ferris, Alfred W Rademaker, Urjeet A Patel, Sandeep Samant
BACKGROUND: The National Quality Forum has endorsed quality-improvement measures for multiple cancer types that are being developed into actionable tools to improve cancer care. No nationally endorsed quality metrics currently exist for head and neck cancer. METHODS: The authors identified patients with surgically treated, invasive, head and neck squamous cell carcinoma in the National Cancer Data Base from 2004 to 2014 and compared the rate of adherence to 5 different quality metrics and whether compliance with these quality metrics impacted overall survival...
July 20, 2017: Cancer
https://www.readbyqxmd.com/read/28726169/comparison-of-the-systemic-and-local-pharmacokinetics-of-clonidine-mucoadhesive-buccal-tablets-with-reference-clonidine-oral-tablets-in-healthy-volunteers-an-open-label-randomised-cross-over-trial
#9
Bérangère Vasseur, Alain Dufour, Laetitia Houdas, Helen Goodwin, Kathryn Harries, Neslihan Yesiltas Emul, Simon Hutchings
INTRODUCTION: The clonidine mucoadhesive buccal tablet (MBT) is a novel delivery system resulting in high and sustained concentrations of clonidine in the oral cavity. In a phase II clinical trial, clonidine MBT reduced the incidence of severe oral mucositis (OM) compared to placebo in head and neck cancer patients undergoing chemoradiation. This study compared the pharmacokinetics (PK), safety and tolerability of clonidine MBT with a reference oral tablet (OT). METHODS: This was a randomised, three-period, single-dose crossover study in 36 healthy subjects aged 18-50 years...
July 19, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28717702/management-of-chemoradiation-induced-mucositis-in-head-and-neck-cancers-with-oral-glutamine
#10
Lucy Pattanayak, Niharika Panda, Manoj Kumar Dash, Sumita Mohanty, Sagarika Samantaray
PURPOSE: Head and neck cancers are the third most common cancers worldwide. Oral mucositis is the most common toxicity seen in patients who receive chemoradiation to treat head and neck cancer. The aim of this study was to evaluate the efficacy and safety of oral glutamine supplementation in these patients. MATERIALS AND METHODS: From December 2013 to December 2014, we randomly assigned to two arms 162 patients who had squamous cell carcinoma of the head and neck...
August 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28702409/phase-iib-trial-comparing-two-concurrent-cisplatin-schedules-in-locally-advanced-head-and-neck-cancer
#11
Lekha Madhavan Nair, R Rejnish Kumar, Kainickal Cessal Thomachan, Malu Rafi, Preethi Sara George, K M Jagathnath Krishna, Kunnambath Ramadas
BACKGROUND: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m(2)) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent cisplatin regimens. OBJECTIVES: The objective of this study was to compare the efficacy and toxicities of 3 weekly cisplatin (100 mg/m(2)) with weekly cisplatin (40 mg/m(2)) concurrently with radiation in patients with locally advanced head and neck cancer...
April 2017: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/28700650/sulforaphane-enhances-irradiation-effects-in-terms-of-perturbed-cell-cycle-progression-and-increased-dna-damage-in-pancreatic-cancer-cells
#12
Patrick Naumann, Jakob Liermann, Franco Fortunato, Thomas E Schmid, Klaus-Josef Weber, Jürgen Debus, Stephanie E Combs
BACKGROUND: Sulforaphane (SFN), an herbal isothiocyanate enriched in cruciferous vegetables like broccoli and cauliflower, has gained popularity for its antitumor effects in cell lines such as pancreatic cancer. Antiproliferative as well as radiosensitizing properties were reported for head and neck cancer but little is known about its effects in pancreatic cancer cells in combination with irradiation (RT). METHODS: In four established pancreatic cancer cell lines we investigated clonogenic survival, analyzed cell cycle distribution and compared DNA damage via flow cytometry and western blot after treatment with SFN and RT...
2017: PloS One
https://www.readbyqxmd.com/read/28688700/a-phase-i-study-of-cabazitaxel-in-combination-with-platinum-and-5-fluorouracil-pf-in-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-la-scchn
#13
Nadia Camille, John Rozehnal, Elizabeth Roy, Dariusz Uczkowski, Ashely Olson, Eric Genden, Marita Teng, Richard Bakst, Vishal Gupta, Marshall Posner, Krzysztof Misiukiewicz
BACKGROUND: There is a clinical need to improve outcomes for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), especially in Human Papilloma Virus (HPV) negative and HPV positive subtypes with a significant history of tobacco use. In animal models bearing SCCHN, Cabazitaxel showed an excellent response rate compared to docetaxel and might prove useful in treatment of patients. The primary objective of this study was to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of cabazitaxel when combined with cisplatin and 5-fluorouracil (PF) in induction chemotherapy (IC) for patients with SCCHN...
August 2017: Oral Oncology
https://www.readbyqxmd.com/read/28688677/long-term-survival-of-a-randomized-phase-iii-trial-of-head-and-neck-cancer-patients-receiving-concurrent-chemoradiation-therapy-with-or-without-low-level-laser-therapy-lllt-to-prevent-oral-mucositis
#14
Héliton S Antunes, Daniel Herchenhorn, Isabele A Small, Carlos M M Araújo, Celia Maria Pais Viégas, Gabriela de Assis Ramos, Fernando L Dias, Carlos G Ferreira
BACKGROUND: The impact of low-level laser therapy (LLLT) to prevent oral mucositis in patients treated with exclusive chemoradiation therapy remains unknown. This study evaluated the overall, disease-free and progression-free survival of these patients. METHODS: Overall, disease-free and progression-free survival of 94 patients diagnosed with oropharynx, nasopharynx, and hypopharynx cancer, who participated on a phase III study, was evaluated from 2007 to 2015. The patients were subjected to conventional radiotherapy plus cisplatin every 3weeks...
August 2017: Oral Oncology
https://www.readbyqxmd.com/read/28686330/gstp1-c-313a-g-xpd-c-934g-a-xpf-c-2505t-c-and-casp9-c-1339a-g-polymorphisms-and-severity-of-vomiting-in-head-and-neck-cancer-patients-treated-with-cisplatin-chemoradiation
#15
Juliana Carron, Leisa Lopes-Aguiar, Ericka Francislaine Dias Costa, Guilherme Augusto Silva Nogueira, Tathiane Regine Penna Lima, Eder Carvalho Pincinato, Marilia Berlofa Visacri, Júlia Coelho França Quintanilha, Patrícia Moriel, Gustavo Jacob Lourenço, Carmen Silvia Passos Lima
Cisplatin (CDDP) chemotherapy associated with radiation (RT) has been used in advanced head and neck squamous cell carcinoma (HNSCC) patients, and vomiting is a common side effect during treatment. This prospective study aimed to identify the roles of GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G, XPC c.2815A>C, XPD c.934G>A and c.2251A>C, XPF c.2505T>C, ERCC1 c.354C>T, MLH1 c.-93G>A, MSH2 c.211 + 9C>G, MSH3 c.3133G>A, EXO1 c.1765G>A, TP53 c.215G>C, CASP3 c.-1191A>G and c...
July 7, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28657801/beneficial-effects-of-adjuvant-melatonin-in-minimizing-oral-mucositis-complications-in-head-and-neck-cancer-patients-receiving-concurrent-chemoradiation
#16
Kittipong Onseng, Nutjaree Pratheepawanit Johns, Thanut Khuayjarernpanishk, Suphat Subongkot, Aroonsri Priprem, Cameron Hurst, Jeffrey Johns
OBJECTIVES: Oral mucositis is a major cause of pain and delayed cancer treatment leading to poor survival in head and neck cancer patients receiving concurrent chemoradiation. The study evaluated the effect of adjuvant melatonin on minimizing oral mucositis complications to reduce these treatment delays and interruptions. DESIGN: A randomized, double-blind, double dummy, placebo-controlled clinical trial. SETTING: Ubon Ratchathani Cancer Hospital, Thailand...
June 28, 2017: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/28649557/dusquetide-reduction-in-oral-mucositis-associated-with-enduring-ancillary-benefits-in-tumor-resolution-and-decreased-mortality-in-head-and-neck-cancer-patients
#17
Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T Sonis, Richard Straube, Oreola Donini
Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality...
September 2017: Biotechnology Reports
https://www.readbyqxmd.com/read/28633765/neck-dissection-for-unknown-cancer-of-the-head-and-neck-in-the-era-of-chemoradiation
#18
Mark J Amsbaugh, Mehran Yusuf, Jeremy Gaskins, Craig Silverman, Kevin Potts, Jeffrey Bumpous, Rebecca Redman, Cesar Perez, Neal Dunlap
PURPOSE: To report outcomes for patients with cervical lymph node metastases from an unknown primary site of the head and neck treated with either non-operative therapy or neck dissection followed by adjuvant therapy. MATERIALS AND METHODS: All patients with squamous cell carcinoma of an unknown primary site of the head or neck seen between 2003 and 2013 were reviewed. The Kaplan-Meier method was used to estimate overall survival, local recurrence free survival, loco-regional recurrence free survival, and progression free survival...
June 14, 2017: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/28608731/survival-outcomes-in-patients-with-t2n0m0-stage-ii-squamous-cell-carcinoma-of-the-larynx
#19
Danielle L Gainor, Emily Marchiano, Emily Bellile, Matthew E Spector, Jeremy M G Taylor, Gregory T Wolf, Norman D Hogikyan, Mark E Prince, Carol R Bradford, Avraham Eisbruch, Francis Worden, Andrew G Shuman
Objective Emerging data have demonstrated suboptimal outcomes among patients with stage II larynx cancer. Our objective is to report survival outcomes for T2N0M0 larynx cancer and to determine the cause-specific survival. Study Design Case series with planned data collection. Setting Tertiary academic center. Subjects Adults with T2N0M0 squamous cell carcinoma of the larynx treated with curative intent. Methods A head and neck cancer epidemiology database was queried for eligible subjects from 2003 to 2014...
June 1, 2017: Otolaryngology—Head and Neck Surgery
https://www.readbyqxmd.com/read/28602414/the-older-adult-with-locoregionally-advanced-head-and-neck-squamous-cell-carcinoma-knowledge-gaps-and-future-direction-in-assessment-and-treatment
#20
REVIEW
Ronald Maggiore, Zachary S Zumsteg, Karlynn BrintzenhofeSzoc, Kelly M Trevino, Ajeet Gajra, Beatriz Korc-Grodzicki, Joel B Epstein, Stewart M Bond, Ira Parker, Julie A Kish, Barbara A Murphy, Noam A VanderWalde
Older adults with head and neck squamous cell carcinoma (HNSCC) pose unique treatment and supportive care challenges to oncologists and other cancer care providers. The majority of patients with HNSCC present with locoregionally advanced disease, for which combined-modality treatment integrating chemotherapy and radiation therapy is often necessary to maximize tumor control. However, applying these approaches to an older population with concomitant comorbidities and a higher risk of functional impairments remains challenging and is exacerbated by the paucity of studies involving older adults...
July 15, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
36807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"